A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease

[1]  Sonja W. Scholz,et al.  Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study , 2018, The Lancet Neurology.

[2]  A. Fagan,et al.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy , 2017, Nature.

[3]  C. Jack,et al.  MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies , 2016, Alzheimer's & Dementia.

[4]  Keith A. Johnson,et al.  Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. , 2016, JAMA neurology.

[5]  K. Zahs,et al.  Caspase-2 cleavage of tau reversibly impairs memory , 2016, Nature Medicine.

[6]  D. Allsop,et al.  Effects of different isoforms of apoE on aggregation of the α‐synuclein protein implicated in Parkinson’s disease , 2016, Neuroscience Letters.

[7]  M. Tiwari,et al.  Caspase-2 resides in the mitochondria and mediates apoptosis directly from the mitochondrial compartment , 2016, Cell Death Discovery.

[8]  L. Greene,et al.  Caspase-2 Is Essential for C-jun Transcriptional Activation and Bim Induction in Neuron Death Nih Public Access Author Manuscript Proteins Were Detected Using Either Enhanced Chemiluminescence , 2022 .

[9]  C. Bouras,et al.  Neuropathology of dementia in a large cohort of patients with Parkinson's disease. , 2013, Parkinsonism & related disorders.

[10]  J. Pozueta,et al.  Caspase-2 is required for dendritic spine and behavioral alterations in J20 APP transgenic mice , 2013, Nature Communications.

[11]  Daniel Weintraub,et al.  APOE ε4 increases risk for dementia in pure synucleinopathies. , 2013, JAMA neurology.

[12]  M. Nalls,et al.  A large study reveals no association between APOE and Parkinson's disease , 2012, Neurobiology of Disease.

[13]  D. Ehrnhoefer,et al.  Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease , 2011, Molecular Neurodegeneration.

[14]  A. Di Polo,et al.  Ocular neuroprotection by siRNA targeting caspase-2 , 2011, Cell Death and Disease.

[15]  M. Tiwari,et al.  A knockout of the caspase 2 gene produces increased resistance of the nigrostriatal dopaminergic pathway to MPTP-induced toxicity , 2011, Experimental Neurology.

[16]  J. Kulisevsky,et al.  Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. , 2011, Archives of neurology.

[17]  K. Ashe,et al.  Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.

[18]  M. Ban,et al.  Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease , 2007 .

[19]  Arlan Richardson,et al.  Caspase-2 deficiency enhances aging-related traits in mice , 2007, Mechanisms of Ageing and Development.

[20]  S. Srinivasula,et al.  Oligomerization Is a General Mechanism for the Activation of Apoptosis Initiator and Inflammatory Procaspases* , 2003, The Journal of Biological Chemistry.

[21]  J. Perlmutter,et al.  Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. , 2002, Genomics.

[22]  S. Rabacchi,et al.  Caspase-2 Mediates Neuronal Cell Death Induced by β-Amyloid , 2000, The Journal of Neuroscience.

[23]  S. Shimohama,et al.  Changes in caspase expression in Alzheimer's disease: comparison with development and aging. , 1999, Biochemical and biophysical research communications.

[24]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[25]  S. Rabacchi,et al.  Caspase-2 mediates neuronal cell death induced by beta-amyloid. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.